Back to News
Market Impact: 0.2
Beactica Therapeutics initiates IND-enabling studies for BEA-17, a first-in-class LSD1-CoREST degrader for glioblastoma
Source: PR Newswire
Healthcare & BiotechTechnology & Innovation
Beactica Therapeutics initiated IND-enabling studies for BEA-17, its wholly owned first-in-class oral degrader targeting the epigenetic regulators LSD1 and CoREST. The development milestone advances the Swedish precision-medicine company's preclinical oncology pipeline toward a potential IND filing, though no clinical data, financial details, or regulatory timeline were disclosed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
More News
- How the US midterm elections reflected resistance to data centres
- Elon Musk once said the Cybertruck would be Tesla’s ‘best product ever.’ Now he’s winding down production
- AI Party isn't Ending Because Of The Blue Wave Says Ives
- SoftBank, ABB consider China carve-out to rescue $5.4bn robotics deal
- A ‘geologic freak’ called the Smackover may end America’s lithium dependence on China, and Big Oil is already there
- AI’s Grip on Financial Markets Was Never Clearer on the Way Down